Latest Conference Articles

David Aguilar, MD, of Baylor College of Medicine, discusses the new responsibilities faced by cardiologists with the emerging onset of dual-indication medicines.

Gregg Fonarow, MD, of UCLA, spoke about the benefits of short-term treatment for keeping HF patients out of hospital, and using hospitalization as a time to learn.

Doctors should be asking questions about their patients eating habits and gastrointestinal health when screening for mental illnesses, according to Dr Raison.

There are 3 key conditions that are likely to respond well to treatment with cannabis, with many more likely to be uncovered as research increases.

Kevin Hill, MD, explains how changing cannabis policies will open new doors for clinicians.

Our understanding of the connection between the mind and microbiota has come a long way, but it still has a long way to go, according to Charles L Raison, MD.

Mandeep Mehra, MD, President of the HFSA, discusses the importance of team-based care between physicians, pharmacists, and nurse practitioners in treating heart failure.

Michael Thase, MD, explains the decision making process behind choosing drugs or therapy for patients with different types of depression.

Doris Greenberg, MD, discusses the fine line between Asperger's Syndrome and Autism Spectrum Disorder.

Bertram Pitt, MD, of the University of Michigan School of Medicine, discusses the benefits of subcutaneous furosemide keeping patients from "bouncing back" into the hospital.

Amil Shah, MD, of Harvard Medical School, discusses the utilization of echocardiography - often the first step for the indication of heart failure with preserved ejection fraction - to diagnose patients with the condition and separate them from other morbidities.

James Udelson, MD, the chief of cardiology at Tufts Medical Center, discusses the possibilities offered by the development of subcutaneous furosemide for HF patients in need of diuresis.

Charles L Raison, MD, explains the relationship between mental health and the trillions of microorganisms that live in and on our bodies.

David Boyer, MD, talks about the topline results from a prospective, double-masked phase 2b clinical trial evaluating ALG-1001 compared to Bevacizumab in patients with DME.

Raj Maturi, MD, talks about the use of sirolimus in combination with aflibercept for patients with chronic AMD.

The phase 2 trial results were very positive in regards to its safety endpoints and the efficacy endpoints were very encouraging.

Companies are skirting regulation to be the first to build the next big stem cell therapy, creating clinical concerns and poor patient outcomes.

Intravitreal ranibizumab significantly improved BCVA compared with vPDT for patients with myopic CNV, often after only 1 or 2 injections.

Jay Prensky, MD, talks about the results of the PALADIN real-world study and the use of the fluocinolone acetonide 0.2 ug/day implant in DME patients.

Carl Baker, MD, speaks about factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or Ranibizumab.

Rishi Singh, MD, talks about the prevention of macular edema in patients with diabetic retinopathy undergoing cataract surgery with an intravitreal aflibercept injection.

Jay Prensky, MD, talks about the pluses and clinical implications of doing real-world observational studies as opposed to clinical trials.

Aflibercept reduced macular edema, microaneurysms, leakage, and ischemic burden while improving VA for patients with DME or RVO.

Rishi Singh, MD, talks about the need for a standard definition of identifying macular edema in diabetic patients.

Thomas Ciulla speaks about the “real-world” outcomes for anti-VEGF therapy in patients with diabetic macular edema (DME) in the United States.

The device uses an efficient, user-friendly, smart algorithm to measure contrast function.

Sirolimus plus aflibercept showed marked reduction in intraretinal and subretinal fluid compared with aflibercept alone for patients with wet AMD.

Rajeev Muni speaks about the 1-year results of a randomized trial comparing Pneumatic Retinopexy vs. Vitrectomy in the management of primary Rhegmatogenous Retinal Detachment.

The drug is being tested as a potential nAMD combination therapy with ranibizumab.

In an analysis of dosing subgroups through 96 weeks of the VIEW 1 and 2 trials, aflibercept injections showed similar results in meeting visual acuity endpoints to ranibizumab.